

Pangaea Data joins AstraZeneca Japan's Healthcare Innovation Network

20 April 2022 | News

As a member of the initiative, Pangaea will apply its novel unsupervised natural language processing, natural language generation and automatic machine learning frameworks to address important issues in healthcare in a privacy preserving manner



Pangaea Data, headquartered in London with offices in San Francisco and Hong Kong, is now a member of Innovation Infusion Japan (i2.JP), an open initiative by AstraZeneca Japan that aims to connect healthcare professionals, local governments, academia, and private companies.

The i2.JP initiative draws members from all over the world to jointly work on collective and practical solutions for important issues in healthcare. Participants in the initiative focus on creating solutions and services for patients and healthcare professionals that focus on diagnosis, devices, digital, drugs, and experience design.

Pangaea has developed a software product called Pangaea's Intelligence Extraction and Summarisation (PIES) that uses unsupervised artificial intelligence methods relating to natural language processing and natural language generation to extract and summarize actionable insights from unstructured text, such as doctors' notes, in a privacy preserving manner. Pangaea's solution uses this data to help clinicians characterize difficult to diagnose conditions and has clinically proven to find 6 times more undiagnosed or miscoded patients.

Pangaea has several high impact peer reviewed publications that demonstrate that combining intelligence from unstructured text with structured information such as diagnostic test results has helped clinicians improve patient outcomes by diagnosing at-risk cases earlier (97% accuracy), or by identifying 6 times more undiagnosed and miscoded patients (90% accuracy).